Replies to post #487 on Horizon Therapeutics Public Limited Co (fka HZNP)

[Investor100]

HZNP @ Stockcharts

While most stocks are getting hammered this one is a winner..+18% and making $$$$

Solid volume at 9M shares and solid news taking this one much higher-bank on it!

7:33 am Horizon Pharma sees Q4 revs of $31.9-32.4 mln vs $27.4 mln CIQ est; provides VIMOVO update (HZNP) : Co provides preliminary revenues for the fourth quarter and fiscal year ended December 31, 2013.

For the fourth quarter of 2013, Horizon expects total net revenues of $31.9-32.4 mln vs $27.4 mln CIQ est.
According to Source Healthcare Analytics, total prescriptions for DUEXIS increased 13% in the fourth quarter of 2013 to 63,947 versus 56,673 in the third quarter of 2013.
Approximately 95% of commercially insured patients taking DUEXIS have a co-pay of twenty dollars or less.
According to SHA, total prescriptions for RAYOS increased 18% in the fourth quarter of 2013 to 2,973 versus 2,530 in the third quarter of 2013.
Approximately 95% of commercially insured patients taking RAYOS have a co-pay of less than twenty dollars.
Preliminary unaudited cash and cash equivalents at December 31, 2013 were ~$80.5 million.